Cargando…

IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation

Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yipeng, Pachnikova, Gabriela, Wang, He, Wu, Yaoyao, Przybilla, Dorothea, Schäfer, Reinhold, Chen, Zihao, Zhu, Shaoxing, Keilholz, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392968/
https://www.ncbi.nlm.nih.gov/pubmed/35694767
http://dx.doi.org/10.17305/bjbms.2022.7279
_version_ 1784771169109409792
author Xu, Yipeng
Pachnikova, Gabriela
Wang, He
Wu, Yaoyao
Przybilla, Dorothea
Schäfer, Reinhold
Chen, Zihao
Zhu, Shaoxing
Keilholz, Ulrich
author_facet Xu, Yipeng
Pachnikova, Gabriela
Wang, He
Wu, Yaoyao
Przybilla, Dorothea
Schäfer, Reinhold
Chen, Zihao
Zhu, Shaoxing
Keilholz, Ulrich
author_sort Xu, Yipeng
collection PubMed
description Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC(50) ) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids’ susceptibility to treatment was more complicated; the fitness of IC(50) curves of 2D and 3D tumor cell preclinical models differs significantly. IC(50) curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically.
format Online
Article
Text
id pubmed-9392968
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-93929682022-08-22 IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation Xu, Yipeng Pachnikova, Gabriela Wang, He Wu, Yaoyao Przybilla, Dorothea Schäfer, Reinhold Chen, Zihao Zhu, Shaoxing Keilholz, Ulrich Bosn J Basic Med Sci Research Article Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC(50) ) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids’ susceptibility to treatment was more complicated; the fitness of IC(50) curves of 2D and 3D tumor cell preclinical models differs significantly. IC(50) curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022-08 2022-06-09 /pmc/articles/PMC9392968/ /pubmed/35694767 http://dx.doi.org/10.17305/bjbms.2022.7279 Text en Copyright: © The Author(s) (2022) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Research Article
Xu, Yipeng
Pachnikova, Gabriela
Wang, He
Wu, Yaoyao
Przybilla, Dorothea
Schäfer, Reinhold
Chen, Zihao
Zhu, Shaoxing
Keilholz, Ulrich
IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
title IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
title_full IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
title_fullStr IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
title_full_unstemmed IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
title_short IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
title_sort ic(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392968/
https://www.ncbi.nlm.nih.gov/pubmed/35694767
http://dx.doi.org/10.17305/bjbms.2022.7279
work_keys_str_mv AT xuyipeng ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT pachnikovagabriela ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT wanghe ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT wuyaoyao ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT przybilladorothea ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT schaferreinhold ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT chenzihao ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT zhushaoxing ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation
AT keilholzulrich ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation